Please ensure Javascript is enabled for purposes of website accessibility
Max Macaluso

Max Macaluso

TMFMassimo

Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.

Recent articles

The Best Big Pharma Dividend Stocks?

Tune in as our analysts debate whether Johnson & Johnson, Merck, AstraZeneca, or Bristol-Myers Squibb is the best big pharma dividend stock today.


Market Checkup: September 23

The Motley Fool's health-care show, Market Checkup, for September 23.


Groundbreaking Diabetes Drug Headlines Approval Bonanza

The EU's CHMP issued a positive opinion for Johnson & Johnson's diabetes drug Invokana. Who will the company face off against across the pond?


Prosensa Plunges 70% as Sarepta Soars

How today's clinical trial news affects biotech company Prosensa, its big pharma partner GlaxoSmithKline, and rival Sarepta.


AstraZeneca: Lost Stock or Cheap Turnaround?

Can this big pharma company return to growth?

Market Checkup: September 19, 2013

The Motley Fool's health-care show for September 19.


Google's Next Project: Curing Diseases?

Is Google funding what could become the most revolutionary biotech company in history?


1 Big Pharma Leaps Past Hurdle

Sanofi won EU approval for MS drug Lemtrada this week.


Do Fish Oil Drugmakers Need to Worry About Generics?

A recent court ruling might mean generic Lovaza will hit the market in the near future.


This Dividend Stock's Secret Weapon?

Investors should take a closer look at AbbVie's drug development pipeline.

Market Checkup: Sept. 18, 2013

Today's health-care headlines.


A New Combination Treatment for Big Pharma GlaxoSmithKline?

Glaxo's melanoma cocktail gets priority review from Food and Drug Administration.


A Big Boost or False Hope For This Biotech?

Dendreon's Provenge received approval in the EU. Is this a major opportunity for the struggling biotech?


Market Checkup: September 17, 2013

Decisions from the EU's regulatory agency and a dividend stock to watch.


What's Holding This Big Pharma Back?

The reasons behind AstraZeneca's lackluster performance.

Can Teva Turn Things Around?

The market may not be enthusiastic about Teva's stock, but what can the company do to boost investor confidence?


1 Dividend Stock for Your Watchlist?

What makes this health-care company a dividend stock to watch?


1 Biotech Going International

What does this EU approval mean for Raptor?


Market Checkup: Sept. 16, 2013

The Motley Fool's health-care show Market Checkup for September 16, 2013.


Is Another Biotech Buyout on the Horizon?

What makes ViroPharma an attractive target for big pharma Sanofi and orphan drug specialist Shire?